Genetic Technologies Limited (NASDAQ:GENE) announced it has filed its Quarterly Activities Report for the Quarter ended March 31, 2014 in accordance with the ASX. Genetic Technologies Limited (ADR) (NASDAQ:GENE) weekly performance is -23.88%. On last trading day company shares ended up $1.02. Analysts mean target price for the company is $2.50. Genetic Technologies Limited (ADR) (NASDAQ:GENE) distance from 50-day simple moving average (SMA50) is -30.34%.
BioTime, Inc. (NYSEMKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine announced, the Company received approximately $6.4 million in equity financing. The funds were raised from current long-term investors in the Company and will be used for funding product development, including this year’s anticipated pivotalRenevia™ clinical trial, as well as other general operating expenses. BioTime, Inc. (NYSEMKT:BTX) shares advanced 2.62% in last trading session and ended the day on $2.35 . BTX Gross Margin is 81.80% and its return on assets is -126.30%. BioTime, Inc. (NYSEMKT:BTX) quarterly performance is -30.88%.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced that Harold E. “Barry” Selick, Ph.D., Chief Executive Officer of Threshold and Cary L. Queen, Ph.D., President of Galaxy Biotech, have been jointly named as finalists for the European Inventor Award 2014 in the “Non-European Countries” category. Their nomination is in recognition of their work while at Protein Design Labs, Inc. (“PDL”) in inventing the humanized monoclonal antibody technology that is embodied in numerous therapeutics such as Avastin® and Herceptin®, as well as Zenapax®, which was the first humanized antibody therapeutic that was approved as a drug by the U.S. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shares moved up 3.59% in last trading session and was closed at $3.75, while trading in range of $3.55 – $3.76 -. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) year to date (YTD) performance is -19.70%.
ArQule, Inc. (NASDAQ:ARQL) announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013. At March 31, 2014, the Company had a total of $85,758,000 in cash, equivalents and marketable securities. ArQule, Inc. (NASDAQ:ARQL) ended the last trading day at $1.40. Company weekly volatility is calculated as 6.08% and price to cash ratio as 1.17. ArQule, Inc. (NASDAQ:ARQL) showed a negative weekly performance of -10.83%.